Mental Health of Pediatric Patients with Cystic Fibrosis after 18 Months on Elexacaftor‐Tezacaftor‐Ivacaftor Therapy
Most pediatric patients with CF did not endorse symptoms of depression or anxiety disorders at ETI initiation. Over the first 18 months of ETI usage, the percentage of patients with these symptoms decreased, suggesting that the percentage of patients experiencing severe symptoms of depression and anxiety may decrease with ongoing use of ETI.
Authors
- Mariah Eisner (ORCID: https://orcid.org/0000-0002-4703-4342)
- Mary Lynn Dell
- Stephanie Sliemers (ORCID: https://orcid.org/0000-0002-6493-7228)
- Anne M. May (ORCID: https://orcid.org/0000-0003-4857-8189)
- Karen McCoy (ORCID: https://orcid.org/0000-0002-3483-0905)
- Kimberly Pasley (ORCID: https://orcid.org/0000-0003-4602-4107)
- Rita Young
Institutions
- Nationwide Children's Hospital (US)
- University of Connecticut (US)
- University of Hartford (US)
- Institute for Community Living (US)
- Hartford Financial Services (United States)
Publication Details
- Journal
- Pediatric Pulmonology
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1002/ppul.27393
- Citations
- 5
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 2.09